Grupo Español de Investigación en Cáncer de Ovario | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder	Active, not recruiting	Phase 3	2026-09-30		NCT05611931
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, adenosquamous carcinoma, carcinoma, cervical carcinoma, cervix disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, mixed neoplasm, neoplasm, uterine disorder	Recruiting	Phase 3	2026-07-07		NCT05581121
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder	Active, not recruiting	Phase 2	2026-06-17		NCT03833479
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer	MMRd/MSI-H Stage II-III Endometrial Cancer	Not yet recruiting	Phase 2	2025-06-10		NCT07013851